About this release
This release (version 20250315) provides the latest updates to the Canadian Clinical Drug Data Set in English and French. A separate InfoScribe location for the French supporting documents, including the French Release Notes, can be found here.
There is no change to the Technical Specification or the Editorial Guidelines.
The Canadian Clinical Drug Data Set is available for browsing and download via the Infoway Terminology Gateway.
Supporting general information can be found on Infoway Canadian Clinical Drug Data Set InfoCentral page.
The following files are available as full release files within this version:
The "Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include “Inactive” content.
NOTE: The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.
This release reflects additions and changes that have occurred in DPD since the last CCDD release.
There is an additional deprecated TM concept in this version due to a change in TM formal name.
tm_code | tm_formal_name | tm_fr_description | Change | New tm_code | New tm_formal_name | New tm_fr_description |
8001940 | sodium oxybate | oxybate de sodium | Deprec | 8002530 | oxybate | oxybate |
The following MP was deprecated as the product was assigned a new DIN.
mp_code | mp_formal_name | mp_fr_description | Change | New mp_code | New mp_formal_name | New mp_fr_description |
77700899 | COSENTYX (secukinumab 150 mg per 1 mL solution for injection syringe) NOVARTIS PHARMACEUTICALS CANADA INC | COSENTYX (sécukinumab 150 mg par 1 mL solution injectable seringue) NOVARTIS PHARMACEUTICALS CANADA INC | Deprec | 02547724 | COSENTYX (secukinumab 150 mg per 1 mL solution for injection syringe) NOVARTIS PHARMACEUTICALS CANADA INC | COSENTYX (sécukinumab 150 mg par 1 mL solution injectable seringue) NOVARTIS PHARMACEUTICALS CANADA INC |
Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at clinicaldrug@infoway-inforoute.ca